Press release
Glioblastoma Multiforme Market to Reach USD 6.91 Billion by 2034
Glioblastoma Multiforme
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70857
The next decade is expected to see significant changes in GBM treatment strategies, with novel targeted therapies, immunotherapies, tumor-treating fields (TTF) technology, and personalized medicine approaches entering clinical practice. The market will benefit from ongoing R&D investments, expanded clinical trial activity, and improved neuro-oncology infrastructure worldwide.
Market Overview
• Market Size (2024): USD 3.64 billion
• Forecasted Market Size (2034): USD 6.91 billion
• CAGR (2024-2034): ~6.5%
• Key Drivers: Expanding research in targeted and immune-based therapies, increasing incidence of GBM, and technological advancements in diagnostics.
• Challenges: Treatment resistance, poor prognosis, and limited curative options.
• Leading Players: F. Hoffmann-La Roche Ltd., Novocure Ltd., Merck & Co., Amgen Inc., Bristol Myers Squibb, Pfizer Inc., and Denovo Biopharma.
Segmentation Analysis
By Treatment Type
• Surgery
• Radiation Therapy
• Chemotherapy (Temozolomide, Carmustine)
• Targeted Therapy (VEGF inhibitors, EGFR inhibitors)
• Immunotherapy (Checkpoint inhibitors, CAR-T therapy)
• Tumor Treating Fields (TTF)
By Drug Class
• Alkylating Agents
• Anti-angiogenic Agents
• EGFR Inhibitors
• Immune Checkpoint Inhibitors
• Experimental Agents
By End Use
• Hospitals & Cancer Centers
• Specialty Clinics
• Research & Academic Institutes
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Segmentation Summary
While temozolomide and radiation remain the standard-of-care, targeted therapies and TTF devices are gaining ground, especially in recurrent GBM cases.
Explore Full Report here: https://exactitudeconsultancy.com/reports/70857/glioblastoma-multiforme-report-glioblastoma-multiforme-market
Regional Analysis
North America
• Holds ~45% of global market share in 2024.
• Strong presence of clinical trials and FDA-approved advanced therapies.
Europe
• Widespread adoption of novel devices like Novocure's Optune®.
• EMA approvals accelerating targeted therapy access.
Asia-Pacific
• Fastest-growing region (CAGR > 8%).
• Rising healthcare investment and expansion of neuro-oncology centers in China, Japan, and South Korea.
Middle East & Africa
• GCC countries leading with improved access to advanced neurosurgical facilities.
Latin America
• Brazil and Argentina investing in specialized brain cancer treatment centers.
Regional Summary
North America dominates revenue share, but Asia-Pacific is set for the highest growth, driven by expanding healthcare infrastructure and clinical trial participation.
Market Dynamics
Key Growth Drivers
1. Rising GBM incidence in aging populations.
2. Increased R&D investment in targeted and immune-based therapies.
3. Technological advances in neuroimaging for earlier detection.
4. Regulatory incentives for orphan drug development.
Key Challenges
1. Tumor heterogeneity complicating drug efficacy.
2. High relapse rates post-standard treatment.
3. High treatment costs limiting access in developing countries.
4. Blood-brain barrier (BBB) limiting drug delivery.
Latest Trends
• Use of liquid biopsy for tumor monitoring and mutation profiling.
• Trials combining immunotherapy with radiotherapy for synergistic effects.
• Development of next-generation TTF devices for better patient compliance.
• Application of AI in brain tumor imaging for faster diagnosis.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=70857
Competitor Analysis
Major Players
• F. Hoffmann-La Roche Ltd. (Avastin® - Bevacizumab)
• Novocure Ltd. (Optune® - Tumor Treating Fields device)
• Merck & Co., Inc. (Keytruda® - Pembrolizumab)
• Amgen Inc.
• Bristol Myers Squibb (Opdivo® - Nivolumab)
• Pfizer Inc.
• Denovo Biopharma
• Kintara Therapeutics, Inc.
• Celldex Therapeutics
• ImmunoCellular Therapeutics Ltd.
• DNAtrix Inc.
• OncoCyte Corporation
• Tocagen Inc.
• VBL Therapeutics
• Ziopharm Oncology, Inc.
Competitive Summary
The GBM market is heavily research-driven, with innovation focusing on crossing the BBB, personalized therapy regimens, and device-drug combinations to extend patient survival.
Conclusion
Glioblastoma multiforme remains one of the most challenging cancers to treat, but emerging therapies and technologies are providing new hope. By 2034, the integration of precision oncology, immunotherapy, and device-based treatments will significantly expand treatment possibilities.
Opportunities include:
• Advancing BBB-penetrating therapeutics.
• Combining TTF with targeted/immunotherapies.
• Expanding access to clinical trials in emerging markets.
This report is also available in the following languages : Japanese (多形性膠芽腫レポート 多形性膠芽腫市場), Korean (다형성교모세포종 보고서 다형성교모세포종 시장), Chinese (多形性胶质母细胞瘤报告多形性胶质母细胞瘤市场), French (Rapport sur le glioblastome multiforme Marché du glioblastome multiforme), German (Glioblastoma Multiforme-Bericht Glioblastoma Multiforme-Markt), and Italian (Rapporto sul glioblastoma multiforme Mercato del glioblastoma multiforme), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/70857/glioblastoma-multiforme-report-glioblastoma-multiforme-market#request-a-sample
Our More Reports:
Hearing Aid Devices Market
https://exactitudeconsultancy.com/reports/70776/hearing-aid-devices-market
Powered Surgical Instrument Market
https://exactitudeconsultancy.com/reports/70778/powered-surgical-instrument-market
Autosomal Dominant Polycystic Kidney Disease Market
https://exactitudeconsultancy.com/reports/70780/autosomal-dominant-polycystic-kidney-disease-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Glioblastoma Multiforme Market to Reach USD 6.91 Billion by 2034 here
News-ID: 4143973 • Views: …
More Releases from Exactitude Consultancy
Hypertrophic Cardiomyopathy Market to Reach USD 3.21 Billion by 2034, Growing at …
Introduction
Hypertrophic cardiomyopathy (HCM) is a genetic heart disorder characterized by abnormal thickening of the heart muscle, which can impair blood flow and increase the risk of arrhythmias, heart failure, and sudden cardiac death. Once managed primarily through beta-blockers, calcium channel blockers, and invasive procedures, the HCM treatment landscape has expanded with the approval of targeted therapies such as cardiac myosin inhibitors.
Growing awareness of genetic cardiovascular diseases, advances in molecular diagnostics,…
Biologics Contract Research Organization (CRO) Market to Reach USD 37.9 Billion …
Introduction
Biologics-including monoclonal antibodies, vaccines, recombinant proteins, and advanced therapies-are at the forefront of modern medicine. Their development, however, requires significant expertise, advanced infrastructure, and compliance with stringent regulatory standards. To meet these demands, pharmaceutical and biotechnology companies are increasingly outsourcing to Contract Research Organizations (CROs) specializing in biologics.
Biologics CROs provide services spanning discovery, preclinical research, clinical trials, bioanalytical testing, and regulatory consulting. With the rise of biologics, biosimilars, and advanced…
Niemann-Pick Disease Market to Reach USD 1.02 Billion by 2034, Growing at 10.6% …
Introduction
Niemann-Pick disease (NPD) is a group of rare, inherited lysosomal storage disorders caused by mutations that disrupt lipid metabolism, leading to progressive neurological decline, organ dysfunction, and premature death. The condition is categorized into several subtypes (A, B, and C), each varying in severity and progression.
Historically, treatment has been limited to palliative and supportive care. However, the landscape is changing rapidly with the development of enzyme replacement therapies (ERT), substrate…
PERK Inhibitors Market Forecast: USD 3.2 Billion by 2034 | Major Participants: N …
The fight against cancer and neurodegenerative diseases has brought the spotlight on the PERK (Protein kinase RNA-like endoplasmic reticulum kinase) pathway, a critical regulator of the unfolded protein response. PERK inhibitors are designed to modulate this pathway, reducing stress-induced cell death and playing a pivotal role in oncology, neurodegenerative research, and metabolic disorders. As precision medicine continues to gain traction, PERK inhibitors are attracting significant attention from both biotech firms…
More Releases for Glioblastoma
Key Trends Shaping the Future Glioblastoma Multiforme Market From 2025-2034: Adv …
Which drivers are expected to have the greatest impact on the over the glioblastoma multiforme market's growth?
The growing number of brain disorder cases is anticipated to boost the glioblastoma multiforme market in the coming years. A brain disorder is a condition that affects the brain's structure or function, leading to cognitive, emotional, or physical difficulties. The rise in brain disorder cases is attributed to factors such as an aging population,…
Glioblastoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Glioblastoma Pipeline Insight, 2024," report provides comprehensive insights about 195+ companies and 210+ pipeline drugs in Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Glioblastoma Pipeline Report
* DelveInsight's Glioblastoma pipeline report depicts…
Glioblastoma Multiforme Market Insights, Forecast to 2031
"Glioblastoma Multiforme Market 2024,"
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Glioblastoma Multiforme market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market shares held by major segments within the Glioblastoma Multiforme industry, providing stakeholders with a nuanced perspective on market…
Beyond Bravery - Bill Fitzpatrick's Fight Against Glioblastoma
Bill Fitzpatrick Jr, a retired sales professional from GE, has recently ventured into the world of writing with his debut book. Inspired by his experiences during taking care of his wife, who had Glioblastoma, Bill felt the need to share his journey and provide support to other families navigating similar challenges. In this article, we will dive into Bill's background, his motivation for becoming an author, details about his latest…
Recurrent Glioblastoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Recurrent Glioblastoma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Recurrent Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Recurrent Glioblastoma Pipeline Report
DelveInsight's Recurrent Glioblastoma…
Revolutionizing Glioblastoma Treatment Strategies: A Deep Dive into the Glioblas …
The Glioblastoma Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Glioblastoma treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the Glioblastoma pipeline landscape and fostering the potential growth of Glioblastoma therapeutic advancements.
Key Takeaways from the Glioblastoma Pipeline Report
• DelveInsight's Glioblastoma pipeline report depicts a robust space with 195+ active players…
